JBIO Reports $336M Cash Runway to 2028, Advances JADE101 Phase 1 Data Q2 2026, JADE201 RA Trial Q2 2026, JADE301 Phase 1 H1 2027
Jade Biosciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $18.59
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS